申请人:TOKYO TANABE COMPANY LIMITED
公开号:EP0820982A1
公开(公告)日:1998-01-28
4-amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds represented by the following general formula:
(wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group which may have a substituent, or a phenyl group which may have a hydroxyl group, lower alkoxy group, amino group, nitro group, carboxyl group, lower alkoxycarbonyl group or halogen atom, or R1, R2 and the nitrogen atom together represent a saturated nitrogen heterocyclic group; R3 represents a hydrogen atom, a lower alkyl group or a lower aliphatic acyl group); and W represents an oxo group, oxime group or oxime ether group; and their pharmacologically acceptable salts and solvates.
The 4-amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds exhibit an effect against rat peripheral arterial occlusion models, spontaneous hypertensive rats and histamine-induced airway contraction models, and are thus useful as remedy for hypertension, peripheral arterial occlusion and bronchial asthma.
4-
氨基-5-
氧基-2,6,6-三
甲基-2-
环庚烯化合物,其通式如下:
(其中 R1 和 R2 各自独立地代表一个
氢原子、一个可带有取代基的烷基或一个可带有羟基、低级烷
氧基、
氨基、硝基、羧基、低级烷
氧羰基或卤素原子的
苯基,或 R1、R2 和
氮原子共同代表一个饱和
氮杂环基团;R3代表
氢原子、低级烷基或低级
脂肪酰基);W代表羰基、
肟基或
肟醚基;以及它们的药理学上可接受的盐和溶剂。
4-
氨基-5-
氧基-2,6,6-三
甲基-2-
环庚烯化合物对大鼠外周动脉闭塞模型、自发性高血压大鼠和
组胺诱导的气道收缩模型均有疗效,因此可用于治疗高血压、外周动脉闭塞和支气管哮喘。